BCMA Targeted Therapies Summit

Card image cap

Built with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused BCMA Targeted Therapies Summit will share the field’s cutting-edge and aggressive scientific advances of BCMA therapies within multiple myeloma.

This summit is the first of its kind, uniting thought leaders in BCMA therapeutics drug development to discuss their challenges and future directions, with the aim to overcome key obstacles when designing a clinical trial, addressing the rationale for combinations and determining mechanisms of relapse.

The race for the next approval may be on but make sure you join over 80 of your peers at the only definitive digital platform dedicated to bringing together BCMA experts from large pharma, innovative biotech, research institutes and most importantly, the end users; the patients to participate in cross-disciplinary discussions.

Whether you’re developing an ADC, a CAR-T or a Bispecific for the BCMA Target, this is the meeting for you.

For the full agenda and speaker faculty, click here.

Hanson Wade

12 March, 2021